AstraZeneca opens $1 billion R&D center in Cambridge, Massachusetts
AstraZeneca inaugurated a new research and development campus in Kendall Square, Cambridge, Massachusetts. The 570,000‑square‑foot, 18‑story facility will host nearly 2,000 scientists and focus on oncology, cell therapy, chronic and rare diseases. The project is part of a broader U.S. investment programme of $50 billion and will expand the company’s Massachusetts workforce by more than 50 percent.
Why it matters
The expansion increases AstraZeneca’s R&D capacity in a key U.S. market, supporting its goal to generate about half of its revenue from the United States by 2030. The new centre also underpins the company’s “Ambition 2030” plan to reach $80 billion in annual revenue.
Key facts
- 1AstraZeneca is investing $1 billion in the new Cambridge centre. investingnews.com
- 2The facility covers 570,000 sq ft and rises 18 stories. investingnews.com
- 3Nearly 2,000 researchers will work at the site. investingnews.com
- 4The Massachusetts workforce will grow by over 50 percent. investingnews.com
- 5The investment is part of a $50 billion U.S. investment plan. investingnews.com
Summary written by AlphAI from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.